Skip to content
DataLookout
Menu

NCT07648225

UBT251 Injection Phase Ⅲ Study (Overweight or Obesity)

StatusActive, Not Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 25 words
    • Trial status changed: Not Yet Recruiting → Active, Not Recruiting
    • Start date changed from estimate of Jul 31, 2026 to Sep 4, 2026
    • Site details revised
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Body Weight
Timeframe: Week 52

Secondary (8)

Waist Circumference
BMI
Systolic blood pressure
Diastolic blood pressure
HbA1c
Show 3 moreShow less
Fasting Serum Lipids
SF-36 v2 scores
Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) scores

Arms and interventions

UBT251 Injection 4.0 mgExperimental

Each subject will receive UBT251 Injection s.c. once weekly for 52 weeks. Each dose group will be titrated starting from the initial dose, administered once weekly, and escalated to the next dose after 4 weeks until the target maintenance dose is reached, with a total treatment duration of 52 weeks.

UBT251 Injection 6.0 mgExperimental

Each subject will receive UBT251 Injection, s.c. once weekly for 52 weeks. Each dose group will be titrated starting from the initial dose, administered once weekly, and escalated to the next dose after 4 weeks until the target maintenance dose is reached, with a total treatment duration of 52 weeks.

UBT251 Injection Placebo 4.0 mgPlacebo comparator

Each subject will receive UBT251 Injection Placebo, s.c. once weekly for 52 weeks. Each dose group will be titrated starting from the initial dose, administered once weekly, and escalated to the next dose after 4 weeks until the target maintenance dose is reached, with a total treatment duration of 52 weeks.

UBT251 Injection Placebo 6.0 mgPlacebo comparator

Each subject will receive UBT251 Injection Placebo, s.c. once weekly for 52 weeks. Each dose group will be titrated starting from the initial dose, administered once weekly, and escalated to the next dose after 4 weeks until the target maintenance dose is reached, with a total treatment duration of 52 weeks.

Drugs: UBT251 Injection 4.0 mg, UBT251 Injection 6.0 mg, UBT251 Injection Placebo 4.0 mg, UBT251 Injection Placebo 6.0 mg

Sites

1 site in 1 country

  • Peking University People's HospitalBeijing, China